Knocksense: A local content and recommendations platform

{{ subpage.title }}

'Made in India' Covaxin gets emergency use approval for children aged 2-18 years

In a notable moment for India's vaccination program, Bharat Biotech's COVAXIN has received emergency use approval for being administered to children. As per reports, the Subject Expert Committee on COVID-19 has sanctioned the use of Covaxin for kids aged between 2-18. The current decision was taken after extensive deliberations, wherein the authorities studied the various parameters related to trials and vaccine usage.
Read Now Show less

Bharat Biotech's nasal vaccine enters 2nd phase of human trials in Kanpur today

The second phase of human trials for the intra-nasal COVID vaccine, BBV 154, has started in Kanpur from today onwards. As per reports, this innovative vaccine has been developed by Bharat Biotech in collaboration with Washington University School of Medicine. Reportedly, the trial centre set up at Prakhar Hospital received ICMR's approval on Monday and now, the volunteers have been called for this maiden drive.

Read Now Show less